RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Mazdutide is studied as a dual agonist of the GLP-1 and glucagon receptors. Its published clinical program includes randomized trials examining body weight in adults with obesity and blood glucose in adults with type 2 diabetes. These studies provide evidence about defined pharmaceutical formulations in selected populations, with gastrointestinal adverse events as an important part of the findings. They do not establish that a research material with the same name is interchangeable with the trial product. This overview explains three major studies and the limits of comparing their results. [1–3]
WHAT DOES DUAL RECEPTOR AGONISM MEAN?
An agonist activates a receptor, a protein that receives a biological signal. Mazdutide was developed to act at both GLP-1 and glucagon receptors rather than only one of these targets. That description identifies a research strategy; it does not, by itself, demonstrate a particular clinical outcome. Outcomes require measurement in a suitable study with a comparator. The trials below address different questions and should be read separately. [1–3]
GLORY-1: WEIGHT CHANGE OVER 48 WEEKS
The GLORY-1 trial randomly assigned 610 Chinese adults with obesity or overweight to two mazdutide groups or placebo. Its primary assessment was at week 32, when average body-weight changes were approximately minus 10.1% and minus 12.6% in the active groups, compared with plus 0.5% with placebo. At week 48, the corresponding changes were approximately minus 11.0%, minus 14.0% and plus 0.3%. [1]
Those are group averages from a controlled trial, not a prediction for an individual. Keeping the assessment week attached to each figure also matters: the week-32 and week-48 results are not interchangeable. The placebo comparison supports a treatment effect under the study conditions, but it does not answer every question about long-term outcomes or other populations.
GLORY-2: A DIFFERENT STUDY POPULATION AND DURATION
GLORY-2 evaluated a different mazdutide regimen over 60 weeks in Chinese adults with a body mass index of at least 30. Of 462 randomized participants, 461 received study treatment and entered the analyses. The population included people with and without type 2 diabetes. Mean body weight decreased by approximately 16.7% with mazdutide and 1.5% with placebo. Both groups received diet and physical-activity advice. [2]
Vomiting, nausea and diarrhea were common in the active group, and 2.9% discontinued study treatment because of adverse events. Most reported gastrointestinal events were mild or moderate. The larger weight-change figure should not be presented as proof that this regimen is universally better than those in GLORY-1: the studies differed in design, participants and follow-up. [2]
DREAMS-2: A BLOOD-GLUCOSE QUESTION
DREAMS-2 compared mazdutide with dulaglutide in 731 Chinese adults with type 2 diabetes receiving background oral medications. At 28 weeks, the tested mazdutide regimens reduced HbA1c more than the particular dulaglutide regimen used in the trial. HbA1c is a marker of blood-glucose exposure over preceding months. The between-group differences were approximately 0.24 and 0.30 percentage points. [3]
This was an active-comparator diabetes study. It should not be described as a direct comparison with every GLP-1 medicine or every possible comparator regimen. A change in HbA1c is also a different endpoint from a demonstrated reduction in cardiovascular events or mortality.
HOW TO READ THE EVIDENCE RESPONSIBLY
The most useful interpretation keeps the formulation, population, comparator, analysis and follow-up together. Combining the largest result from one study with the most favorable safety statement from another produces a misleading picture. Published trial findings support continued scientific evaluation of mazdutide, while leaving questions about durability, broader populations and uncommon adverse outcomes. None of these studies validates a separately sourced research product for personal use.
REFERENCES
1. Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. New England Journal of Medicine. 2025;392:2215–2225.
https://doi.org/10.1056/NEJMoa2411528
2. Gao L, Jiang H, Cai H, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026;336:377–388.
https://doi.org/10.1001/jama.2026.8142
3. Guo L, Zhang B, Xue X, et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026;652:181–188.
https://doi.org/10.1038/s41586-025-10031-z